Based on the outlined principles, we can envisage a multitude of approaches to enhance the cytotoxic anti-tumor activity of human γδ T cells, or to modulate their subset phenotype (Bhat et al., under revision), or to revert their detrimental activity (e.g., regulatory activity and/or high-PD-L1 expression of tumor-infiltrating γδ T cells) (53). The gene discussed is CD274; the disease is neoplasm.